High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up

Neuro-oncology
Lauren E AbreyJ Gregory Cairncross

Abstract

We previously reported a phase 2 trial of 69 patients with newly diagnosed anaplastic or aggressive oligodendroglioma who were treated with intensive procarbazine, CCNU (lomustine), and vincristine (PCV) followed by high-dose thiotepa with autologous stem cell rescue. This report summarizes the long-term follow-up of the cohort of 39 patients who received high-dose thiotepa with autologous stem cell support. Thirty-nine patients with a median age of 43 (range, 18-67) and a median KPS of 100 (range, 70-100) were treated. Surviving patients now have a median follow-up of 80.5 months (range, 44-142). The median progression-free survival is 78 months, and median overall survival has not been reached. Eighteen patients (46%) have relapsed. Neither histology nor prior low-grade oligodendroglioma correlated with risk of relapse. Persistent nonenhancing tumor at transplant was identified in our initial report as a significant risk factor for relapse; however, long-term follow-up has not confirmed this finding. Long-term neurotoxicity has developed only in those patients whose disease relapsed and required additional therapy; no patient in continuous remission has developed a delayed neurologic injury. This treatment strategy affords lo...Continue Reading

References

Feb 1, 1991·Archives of Neurology·J G Cairncross, D R Macdonald
Oct 15, 1994·International Journal of Radiation Oncology, Biology, Physics·D E GannettM S Berger
Oct 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G CairncrossC Schold
Jan 1, 1996·Neurology·W P MasonL M DeAngelis
Dec 13, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M C Chamberlain, P A Kormanik
Oct 17, 1998·Journal of the National Cancer Institute·J G CairncrossD N Louis
Feb 2, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J S SmithR B Jenkins
Dec 23, 2003·Journal of Neuro-oncology·Lauren E AbreyJ Gregory Cairncross
Mar 5, 2004·Expert Opinion on Pharmacotherapy·Riccardo Soffietti
Apr 10, 2004·Journal of Neuro-oncology·S ChibbaroR Gagliardi

❮ Previous
Next ❯

Citations

Oct 13, 2006·Current Treatment Options in Oncology·Lyndon Kim, Michael Glantz
Jun 4, 2011·Neuro-oncology·Andrew B LassmanKatherine S Panageas
Jan 3, 2009·PloS One·Magdalena BenetkiewiczOlivier Delattre
Sep 1, 2014·Seminars in Oncology·Kurt A Jaeckle
Jun 9, 2006·Expert Review of Anticancer Therapy·Jennifer I Stern, Jeffrey J Raizer
Oct 18, 2007·Expert Review of Neurotherapeutics·Riccardo SoffiettiRoberta Rudà
Sep 10, 2011·Revue neurologique·N Sanai, M S Berger
Oct 30, 2007·Neurologic Clinics·Martin J van den Bent
Feb 15, 2008·Critical Reviews in Oncology/hematology·Martin J Van den BentCharles Vecht
Nov 18, 2015·CNS Oncology·Martin J van den Bent
Feb 3, 2009·The Oncologist·Jacolien E C Bromberg, Martin J van den Bent

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.